news
Targeting the clock: new drug disrupts glioblastoma stem cells
Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment.
List view / Grid view
Drug Targets
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
article
AACR 2025: translating research into real-world impact
From first-in-human trial results to emerging AI tools and patient-focused innovations, AACR 2025 offered a clear snapshot of where cancer research is heading. Drug Target Review was on the ground in Chicago to explore the clinical data, technologies, and conversations shaping cancer drug development.
news
New dual-targeting strategy shows promise in treating pancreatic cancer
Researchers at the University of Michigan have discovered a powerful combination therapy that eradicates pancreatic tumours in preclinical models, offering hope for new treatments against one of the most treatment-resistant cancers.
news
Repurposed anti-inflammatory drug may help treat alcohol use disorders
A new study by Scripps Research reveals that apremilast, an FDA-approved anti-inflammatory drug, may help reduce both alcohol consumption and pain sensitivity, offering a potential dual therapy for alcohol use disorder.
news
Targeting zombie cells: a new treatment for chronic back pain
McGill University researchers have found that two drugs can eliminate senescent “zombie cells” in spinal discs, offering a potential new treatment for chronic low back pain.
webinar
Sample Prep 2.0: A New Paradigm for Biopharma Research
29 April 2025 | By LevitasBio
Cell prep is a bottleneck. It’s time to rethink the workflow.
news
Advanced test predicts ALK inhibitor success in lung cancer
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
news
Outsmarting cancer by exploiting DNA repair flaws
Researchers at ETH Zurich in Switzerland have mapped the complex network cells use to repair their genetic material, revealing previously hidden vulnerabilities in cancer cells.
whitepaper
Guide: Create DNA Template for In Vitro mRNA Synthesis
Learn how to simplify the entire DNA template generation workflow, streamlining mRNA therapeutic research.
article
LB-102: Redefining schizophrenia treatment in drug discovery
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
news
Identifying a new target for metabolic liver disease treatment
Scientists have identified protein tyrosine phosphatase delta (PTPRD) as a key regulator of liver metabolism, offering a potential new drug target for treating metabolic liver diseases like MASLD and MASH.
news
PSPC1 knockout slows AML in preclinical models
Scientists at UT Health San Antonio have identified PSPC1 in mouse models as a promising new drug target for acute myeloid leukaemia (AML), a deadly blood cancer with limited treatment options.
webinar
Advancing ADC Development: End-to-End Solutions from Design to Characterization
4 April 2025 | By Eurofins Discovery
Join Dr. Francisca Neethling from Eurofins Discovery to explore the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
news
New approach targets VHR enzyme for sepsis treatment
A new study reveals a promising approach to sepsis treatment by targeting the VHR enzyme using fragment-based drug discovery. This innovative method could lead to more effective therapies for sepsis and other immune-related conditions.
news
Drug OLX-07010 shows promise in treating tau diseases
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
